Table 4 Clinical manifestations of injection drug users and nonaddicts with Staphylococcus aureus endocarditis during 3 months follow-up.
Injection drug users | Nonaddicts | Total | ||||
|---|---|---|---|---|---|---|
Variable | (n = 20) | (n = 54) | (n = 74) | OR | 95% CI | P |
Skin or soft tissue | 12 (60) | 34 (63) | 46 (62) | 0.88 | 0.31–2.53 | 1.00 |
Central intravenous catheter | 0 (0) | 3 (6) | 3 (4) | - | - | 0.56 |
Extracardiac deep infectiona | 17 (85) | 48 (89) | 65 (88) | 0.71 | 0.16–3.15 | 0.70 |
Pneumonia | 14 (70) | 27 (50) | 41 (55) | 2.33 | 0.78–6.98 | 0.19 |
Deep-seated abscessb | 7 (35) | 25 (46) | 32 (43) | 0.63 | 0.22–1.81 | 0.44 |
Osteomyelitis | 6 (30) | 17 (32) | 23 (31) | 0.93 | 0.31–2.85 | 1.00 |
Septic arthritis | 3 (15) | 5 (9) | 8 (11) | 1.73 | 0.37–8.02 | 0.67 |
Urinary tract | 1 (5) | 4 (7) | 5 (7) | 0.66 | 0.07–6.27 | 1.00 |
Recurrent S. aureus bacteremia | 1 (5) | 1 (2) | 2 (3) | 2.79 | 0.17–46.84 | 0.47 |
Mediastinitis | 0 (0) | 9 (17) | 9 (12) | - | - | 0.10 |
Vascular phenomenon | 12 (60) | 19 (35) | 31 (42) | 2.76 | 0.96–7.93 | 0.07 |
Arterial thromboembolic event | 5 (25) | 17 (32) | 22 (30) | 0.73 | 0.23–2.32 | 0.78 |
Heartc | 0 (0) | 11 (20) | 11 (15) | - | - | 0.03 |
Spleen, kidney or liver | 3 (15) | 0 (0) | 3 (4) | - | - | 0.02 |
Cerebral | 4 (20) | 9 (17) | 13 (18) | 1.25 | 0.34–4.63 | 0.74 |
Venous thromboembolic event | 8 (40) | 4 (7) | 12 (16) | 8.33 | 2.15–32.32 | 0.002 |
Pulmonary embolismd | 8 (40) | 2 (4) | 10 (14) | 17.33 | 3.26–92.24 | <0.001 |
Deep venous thrombosis | 0 (0) | 2 (4) | 2 (3) | - | - | 1.00 |